GlaxoSmithKline News and Research

RSS

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

laxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal®XR™ (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures.

29 Jan 2010

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

29 Jan 2010

Rotavirus vaccine could save millions of children in developing countries, studies find

Efforts to vaccinate "infants against rotavirus could save the lives of millions of children in developing nations who would otherwise die from the diarrhea-causing disease, two new studies show," HealthDay/BusinsessWeek reports.

28 Jan 2010

Studies in Mexico and Africa demonstrate the effectiveness of rotavirus vaccine

For the first time ever, studies in Mexico and Africa, published today in the New England Journal of Medicine, demonstrate a reduction in diarrheal disease deaths following rotavirus vaccine introduction in Mexico and vaccine efficacy among impoverished populations in Malawi and South Africa.

28 Jan 2010

New technique could reduce animal use in gene study

A new method of priming early embryos to form embryonic stem (ES) cells has allowed ES cells to be derived from mice used in diabetes research for the first time.

28 Jan 2010

Alli boosts weight loss and reduces excess visceral fat

New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke.

28 Jan 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

African vaccine maker plans to increase production capacity sevenfold by 2013

Biovac Institute, a South African vaccine maker, said Monday that it is working with other major pharmaceutical firms to increase its annual capacity sevenfold to 35 million doses by 2013, Reuters reports.

28 Jan 2010

Researchers renew hope that effective vaccine could be developed against Salmonella infection

Research from Malawi, Birmingham and Liverpool has renewed hope that an effective vaccine could be developed against nontyphoidal strains of Salmonella. The work, funded by the Wellcome Trust and GlaxoSmithKline, suggests that the body's immune system could be primed to tackle even the most resilient of strains.

27 Jan 2010

WHO rejects accusations it mishandled H1N1, updates worldwide stats

WHO spokesperson Gregory Hartl on Monday rejected accusations that the organization miscategorized H1N1 (swine flu) as a pandemic, calling such accusations "irresponsible," the Associated Press/Washington Post reports. "WHO also dismissed claims it colluded with drug companies to bring economic benefit to the industry by playing up the danger of the new H1N1 [swine flu] influenza strain," the news service writes.

27 Jan 2010

CEO Cancer Gold Standard: Four organizations receive accreditation

The American Cancer Society’s Mid-South Division, LiDestri Foods, MDU Resources Group, Inc. and WCA Hospital have received CEO Cancer Gold Standard™ accreditation, recognizing the commitment of these organizations to taking concrete actions to reduce the cancer risk of employees and their families through screenings, early detection, and healthy changes in lifestyle.

25 Jan 2010

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

Andrew Witty, Chief Executive of GlaxoSmithKline, today announced a series of new initiatives targeted at further transforming the company's approach to diseases that disproportionately affect the world's poorest countries. His announcements build on commitments made in 2009 to work in partnership, expand access to medicines and encourage new research into neglected tropical diseases.

22 Jan 2010

DIA Annual EuroMeeting programme in Monaco

The Drug Information Association (DIA) in Europe will host its 22nd Annual EuroMeeting from 8-10 March 2010 in Monaco. The DIA Annual EuroMeeting features more than 110 hot-topic sessions across 13 themes and attracts more than 3,000 professionals from the biopharmaceutical industry, contract service organisations, regulatory agencies, health ministries and academia, as well as patients and students worldwide.

22 Jan 2010

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool.

21 Jan 2010

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

pSivida Corp., a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22.

21 Jan 2010

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

The Biotechnology Industry Organization (BIO) applauds the joint efforts of BIO members GlaxoSmithKline and Alnylam Pharmaceuticals to encourage research to accelerate medical therapies for neglected diseases and today’s announcement of the selection of BIO Ventures for Global Health (BVGH) as the administrator of the Intellectual Property (IP) Pool.

21 Jan 2010

GSK to offer scientists access to compounds, lab space to fight malaria

Drugmaker GlaxoSmithKline (GSK)'s Chief Executive Officer Andrew Witty on Tuesday unveiled the company's plans to allow "free access to its library of 13,500 potential malaria treatments and devote the profits from its experimental [RTS,S] vaccine to battling tropical illnesses that beset poor countries," Bloomberg reports (Randall, 1/20).

21 Jan 2010

Health shares rise with speculation regarding Massachusetts election

Health shares rose Tuesday as traders considered the prospect that a Republican victory in the special Senate election in Massachusetts could jeopardize the health reform legislation.

21 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

WHO, CDC issue H1N1 updates

Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.

19 Jan 2010

GlaxoSmithKline News and Research

GlaxoSmithKline's Lamictal XR Extended-Release Tablets receive FDA approval

FDA grants accelerated approval for GlaxoSmithKline's TYKERB

Rotavirus vaccine could save millions of children in developing countries, studies find

Studies in Mexico and Africa demonstrate the effectiveness of rotavirus vaccine

New technique could reduce animal use in gene study

Alli boosts weight loss and reduces excess visceral fat

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

African vaccine maker plans to increase production capacity sevenfold by 2013

Researchers renew hope that effective vaccine could be developed against Salmonella infection

WHO rejects accusations it mishandled H1N1, updates worldwide stats

CEO Cancer Gold Standard: Four organizations receive accreditation

GSK announces new initiatives for addressing healthcare challenges in the world's poorest countries

DIA Annual EuroMeeting programme in Monaco

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

6th Annual Diabetes Conference to feature ocular drug delivery in diabetic retinopathy

BIO commends GSK and Alnylam’s efforts to foster new therapies for neglected diseases

GSK to offer scientists access to compounds, lab space to fight malaria

Health shares rise with speculation regarding Massachusetts election

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

WHO, CDC issue H1N1 updates

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News